Tissue distribution of 35S-metabolically labeled neublastin (BG00010) in rats.

Bibliographic Details
Title: Tissue distribution of 35S-metabolically labeled neublastin (BG00010) in rats.
Authors: Penner, Natalia1 (AUTHOR) natasha.penner@biogen.com, Purushothama, Shobha1 (AUTHOR), Pepinsky, Blake1 (AUTHOR)
Source: Journal of Pharmaceutical & Biomedical Analysis. May2020, Vol. 184, pN.PAG-N.PAG. 1p.
Subject Terms: *CARRIER proteins, *MOLECULAR weights, *RADICULOPATHY, *TISSUES, *RATS, *PROXIMAL kidney tubules, *PAIN management
Abstract: • Neublastin is a low molecular weight heparin binding protein. • The ADME properties were explored using metabolically 35S-labeled NBN following IV and SC administration. • Counts and intact protein were quantified in tissues and fluids as well as biodistribution in whole body carcasses by QWBA. • This study will aid in the design of ADME studies for other heparin binding proteins. Neublastin (NBN) is a neurotrophic growth factor that promotes the survival and regenerative properties of nociceptive neurons and has been tested in clinical trials as a treatment for neuropathic pain in individuals with sciatica and painful lumbosacral radiculopathy. Like many low molecular weight heparin binding proteins, NBN is rapidly cleared from the blood following systemic administration. To explore ADME properties of NBN in rats, we used metabolically 35S-labeled NBN following IV and SC administration quantifying counts and intact protein in kidney, liver, brain, serum, and urine at 5 min, 8 h, 24 h and 48 h, and biodistribution in whole body carcasses by QWBA at 2, 8, 48, 96, and 168 h post dose. NBN is rapidly taken up by tissues mainly by liver and kidney and then degraded. Products of degradation are excreted in urine or recycled and utilized for resynthesis. The data we generated for NBN provides a first look at the complex clearance mechanisms for this protein and should aid in the design of ADME studies for other heparin binding proteins. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Pharmaceutical & Biomedical Analysis is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
More Details
ISSN:07317085
DOI:10.1016/j.jpba.2020.113154
Published in:Journal of Pharmaceutical & Biomedical Analysis
Language:English